Clinical Trial Update: Efficacy and Safety of Olokizumab in Patients With Progressive Fibrosing Interstitial Lung Diseases [Phase 2, Phase 3]

View source ↗

Summary

This clinical trial update notes a Phase 2/3 study evaluating olokizumab for progressive fibrosing interstitial lung diseases, and the trial is currently recrui…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Interstitial Lung Disease
• Progressive Fibrosing Interstitial Lung Disease

Drugs mentioned

• Olokizumab (olokizumab)

Snippet

Sponsor: R-Pharm International, LLC | Conditions: Lung Diseases, Interstitial | Phase 2, Phase 3 | Status: RECRUITING